skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 238  for All Library Resources

Results 1 2 3 4 5 next page
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis
Material Type:
Article
Add to My Research

Cost-Effectiveness Analysis of Ezetimibe as the Add-on Treatment to Moderate-Dose Rosuvastatin versus High-Dose Rosuvastatin in the Secondary Prevention of Cardiovascular Diseases in China: A Markov Model Analysis

Drug design, development and therapy, 2020-01, Vol.14, p.157-165 [Peer Reviewed Journal]

2020 Yang et al. ;COPYRIGHT 2020 Dove Medical Press Limited ;COPYRIGHT 2020 Dove Medical Press Limited ;2020. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 Yang et al. 2020 Yang et al. ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/dddt.s213968 ;PMID: 32021100

Full text available

2
Therapeutic Effects and Safe Uses of Plant-Derived Polyphenolic Compounds in Cardiovascular Diseases: A Review
Material Type:
Article
Add to My Research

Therapeutic Effects and Safe Uses of Plant-Derived Polyphenolic Compounds in Cardiovascular Diseases: A Review

Drug design, development and therapy, 2021-01, Vol.15, p.4713-4732 [Peer Reviewed Journal]

2021 Alotaibi et al. ;COPYRIGHT 2021 Dove Medical Press Limited ;2021. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 Alotaibi et al. 2021 Alotaibi et al. ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/DDDT.S327238 ;PMID: 34848944

Full text available

3
Evaluation of the cardiovascular effects of varenicline in rats
Material Type:
Article
Add to My Research

Evaluation of the cardiovascular effects of varenicline in rats

Drug design, development and therapy, 2015-01, Vol.9 (default), p.5705-5717 [Peer Reviewed Journal]

COPYRIGHT 2015 Dove Medical Press Limited ;COPYRIGHT 2015 Dove Medical Press Limited ;2015. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2015 Selçuk et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License 2015 ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/DDDT.S92268 ;PMID: 26543352

Full text available

4
Association between glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with cardiovascular complications
Material Type:
Article
Add to My Research

Association between glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with cardiovascular complications

Drug design, development and therapy, 2015-01, Vol.9 (default), p.4735-4749 [Peer Reviewed Journal]

COPYRIGHT 2015 Dove Medical Press Limited ;COPYRIGHT 2015 Dove Medical Press Limited ;2015. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2015 Huri et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License 2015 ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/DDDT.S87294 ;PMID: 26316711

Full text available

5
Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability
Material Type:
Article
Add to My Research

Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability

Drug design, development and therapy, 2017-01, Vol.11, p.811-826 [Peer Reviewed Journal]

COPYRIGHT 2017 Dove Medical Press Limited ;COPYRIGHT 2017 Dove Medical Press Limited ;2017. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2017 Dennison et al. This work is published by Dove Medical Press Limited, and licensed under a Creative Commons Attribution License 2017 ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/DDDT.S126035 ;PMID: 28352156

Full text available

6
SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy
Material Type:
Article
Add to My Research

SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy

Drug design, development and therapy, 2020-01, Vol.14, p.4775-4788 [Peer Reviewed Journal]

COPYRIGHT 2020 Dove Medical Press Limited ;COPYRIGHT 2020 Dove Medical Press Limited ;2020. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 Li and Zhou. 2020 Li and Zhou. ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/DDDT.S269514 ;PMID: 33192053

Full text available

7
Chemical Chaperones to Inhibit Endoplasmic Reticulum Stress: Implications in Diseases
Material Type:
Article
Add to My Research

Chemical Chaperones to Inhibit Endoplasmic Reticulum Stress: Implications in Diseases

Drug design, development and therapy, 2022-01, Vol.16, p.4385-4397 [Peer Reviewed Journal]

2022 Jeon et al. ;COPYRIGHT 2022 Dove Medical Press Limited ;2022 Jeon et al. 2022 Jeon et al. ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/DDDT.S393816 ;PMID: 36583112

Full text available

8
Luteolin Attenuates Atherosclerosis Via Modulating Signal Transducer And Activator Of Transcription 3-Mediated Inflammatory Response
Material Type:
Article
Add to My Research

Luteolin Attenuates Atherosclerosis Via Modulating Signal Transducer And Activator Of Transcription 3-Mediated Inflammatory Response

Drug design, development and therapy, 2019-11, Vol.13, p.3899-3911 [Peer Reviewed Journal]

2019 Ding et al. ;COPYRIGHT 2019 Dove Medical Press Limited ;COPYRIGHT 2019 Dove Medical Press Limited ;2019. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2019 Ding et al. 2019 Ding et al. ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/DDDT.S207185 ;PMID: 31819365

Full text available

9
Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights
Material Type:
Article
Add to My Research

Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights

Drug design, development and therapy, 2022-01, Vol.16, p.2177-2186 [Peer Reviewed Journal]

COPYRIGHT 2022 Dove Medical Press Limited ;2022. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 Chilbert et al. 2022 Chilbert et al. ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/DDDT.S332352 ;PMID: 35832642

Full text available

10
Metformin Activates the AMPK-mTOR Pathway by Modulating lncRNA TUG1 to Induce Autophagy and Inhibit Atherosclerosis
Material Type:
Article
Add to My Research

Metformin Activates the AMPK-mTOR Pathway by Modulating lncRNA TUG1 to Induce Autophagy and Inhibit Atherosclerosis

Drug design, development and therapy, 2020-02, Vol.14, p.457-468 [Peer Reviewed Journal]

2020 You et al. ;COPYRIGHT 2020 Dove Medical Press Limited ;COPYRIGHT 2020 Dove Medical Press Limited ;2020. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 You et al. 2020 You et al. ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/dddt.s233932 ;PMID: 32099330

Full text available

11
Liraglutide and obesity: a review of the data so far
Material Type:
Article
Add to My Research

Liraglutide and obesity: a review of the data so far

Drug design, development and therapy, 2015-01, Vol.9 (default), p.1867-1875 [Peer Reviewed Journal]

COPYRIGHT 2015 Dove Medical Press Limited ;COPYRIGHT 2015 Dove Medical Press Limited ;2015. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2015 Ladenheim. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License 2015 ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/DDDT.S58459 ;PMID: 25848222

Full text available

12
Development and use of sulodexide in vascular diseases: implications for treatment
Material Type:
Article
Add to My Research

Development and use of sulodexide in vascular diseases: implications for treatment

Drug design, development and therapy, 2013-12, Vol.8 (default), p.49-65 [Peer Reviewed Journal]

COPYRIGHT 2014 Dove Medical Press Limited ;COPYRIGHT 2014 Dove Medical Press Limited ;2014. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2014 Coccheri and Mannello. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License 2014 ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/DDDT.S6762 ;PMID: 24391440

Full text available

13
Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey
Material Type:
Article
Add to My Research

Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey

Drug design, development and therapy, 2011, Vol.5 (default), p.325-380 [Peer Reviewed Journal]

2011. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2011 Kones, publisher and licensee Dove Medical Press Ltd. 2011 ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/dddt.s14934 ;PMID: 21792295

Full text available

14
Systematic review and meta-analysis of randomized controlled trials on Wenxin keli
Material Type:
Article
Add to My Research

Systematic review and meta-analysis of randomized controlled trials on Wenxin keli

Drug design, development and therapy, 2016-01, Vol.10, p.3725-3736 [Peer Reviewed Journal]

COPYRIGHT 2016 Dove Medical Press Limited ;COPYRIGHT 2016 Dove Medical Press Limited ;2016. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2016 Wang et al. This work is published and licensed by Dove Medical Press Limited 2016 ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/DDDT.S112333 ;PMID: 27881911

Full text available

15
The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
Material Type:
Article
Add to My Research

The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile

Drug design, development and therapy, 2020-01, Vol.14, p.5515-5520 [Peer Reviewed Journal]

2020 Squillace et al. ;COPYRIGHT 2020 Dove Medical Press Limited ;2020. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 Squillace et al. 2020 Squillace et al. ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/dddt.s274307 ;PMID: 33364747

Full text available

16
Pleiotropic Effects of Ticagrelor: Influence on CYP4F2 Gene and Protein Expression in HUVEC and HepG2, and Escherichia coli Bacterial Survival
Material Type:
Article
Add to My Research

Pleiotropic Effects of Ticagrelor: Influence on CYP4F2 Gene and Protein Expression in HUVEC and HepG2, and Escherichia coli Bacterial Survival

Drug design, development and therapy, 2022-08, Vol.16, p.2559-2568 [Peer Reviewed Journal]

COPYRIGHT 2022 Dove Medical Press Limited ;2022. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2022 Meskauskaite et al. 2022 Meskauskaite et al. ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/DDDT.S357985 ;PMID: 35959420

Full text available

17
Protective Effect Of Vasicine Against Myocardial Infarction In Rats Via Modulation Of Oxidative Stress, Inflammation, And The PI3K/Akt Pathway
Material Type:
Article
Add to My Research

Protective Effect Of Vasicine Against Myocardial Infarction In Rats Via Modulation Of Oxidative Stress, Inflammation, And The PI3K/Akt Pathway

Drug design, development and therapy, 2019-01, Vol.13, p.3773-3784 [Peer Reviewed Journal]

2019 Jiang et al. ;COPYRIGHT 2019 Dove Medical Press Limited ;COPYRIGHT 2019 Dove Medical Press Limited ;2019. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2019 Jiang et al. 2019 Jiang et al. ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/DDDT.S220396 ;PMID: 31802850

Full text available

18
The Synergistic Effects of Astragalus mongholicus and Salvia miltiorrhiza on Coronary Heart Disease Identified by Network Pharmacology and Experiment
Material Type:
Article
Add to My Research

The Synergistic Effects of Astragalus mongholicus and Salvia miltiorrhiza on Coronary Heart Disease Identified by Network Pharmacology and Experiment

Drug design, development and therapy, 2021-01, Vol.15, p.4053-4069 [Peer Reviewed Journal]

2021 Zhang et al. ;COPYRIGHT 2021 Dove Medical Press Limited ;2021. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 Zhang et al. 2021 Zhang et al. ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/DDDT.S326024 ;PMID: 34611395

Full text available

19
Isoborneol Attenuates Low-Density Lipoprotein Accumulation and Foam Cell Formation in Macrophages
Material Type:
Article
Add to My Research

Isoborneol Attenuates Low-Density Lipoprotein Accumulation and Foam Cell Formation in Macrophages

Drug design, development and therapy, 2020, Vol.14, p.167-173 [Peer Reviewed Journal]

2020 Wang et al. ;COPYRIGHT 2020 Dove Medical Press Limited ;COPYRIGHT 2020 Dove Medical Press Limited ;2020. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 Wang et al. 2020 Wang et al. ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/DDDT.S233013 ;PMID: 32021101

Full text available

20
Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway
Material Type:
Article
Add to My Research

Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway

Drug design, development and therapy, 2015-01, Vol.9 (default), p.3217-3229 [Peer Reviewed Journal]

COPYRIGHT 2015 Dove Medical Press Limited ;COPYRIGHT 2015 Dove Medical Press Limited ;2015. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2015 Al-Rasheed et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License 2015 ;ISSN: 1177-8881 ;EISSN: 1177-8881 ;DOI: 10.2147/DDDT.S86431 ;PMID: 26150695

Full text available

Results 1 - 20 of 238  for All Library Resources

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Searching Remote Databases, Please Wait